Last reviewed · How we verify
Citrate-Free Mirikizumab — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Citrate-Free Mirikizumab (Citrate-Free Mirikizumab) — Eli Lilly and Company.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Citrate-Free Mirikizumab TARGET | Citrate-Free Mirikizumab | Eli Lilly and Company | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Citrate-Free Mirikizumab CI watch — RSS
- Citrate-Free Mirikizumab CI watch — Atom
- Citrate-Free Mirikizumab CI watch — JSON
- Citrate-Free Mirikizumab alone — RSS
Cite this brief
Drug Landscape (2026). Citrate-Free Mirikizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/citrate-free-mirikizumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab